Jo Deal, MD
Infectious Disease · Jackson, MSNPI 1003826272
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.0% of the total across 571 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,141 and has fallen 75.4% since, to $526 in 2025. Among infectious disease clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 571 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Insmed, Inc.$1K
- Merck$763
- Gilead$540
- CSL Behring$537
- AbbVie$506
- plus $4K from 23 others
What the payments were for
- Food & beverage$8,40493%
- Education$6297%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 122 | $1,655 |
| Insmed, Inc. | 107 | $1,456 |
| Merck | 39 | $763 |
| Gilead | 26 | $540 |
| CSL Behring | 30 | $537 |
| AbbVie(2 entities) | 42 | $506 |
| Johnson & Johnson | 35 | $476 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $445 |
| Theratechnologies Inc. | 26 | $408 |
| Paratek Pharmaceuticals, Inc. | 20 | $333 |
| Astellas Pharma US Inc | 12 | $299 |
| Grifols USA, LLC | 16 | $283 |
| Shire North American Group Inc | 13 | $211 |
| Philips North America LLC | 11 | $211 |
| Janssen Products, LP | 2 | $169 |
| Tetraphase Pharmaceuticals, Inc. | 11 | $163 |
| Mayne Pharma Commercial LLC | 9 | $152 |
| Pfizer | 5 | $99 |
| Nabriva Therapeutics, PLC | 4 | $67 |
| Melinta Therapeutics, LLC | 3 | $42 |
| Shionogi Inc | 2 | $34 |
| Baxter Healthcare | 2 | $34 |
| Invivyd Inc | 2 | $34 |
| EMD Serono, Inc. | 2 | $30 |
| Boehringer Ingelheim | 1 | $23 |
| Averitas Pharma Inc. | 1 | $20 |
| Eisai Inc. | 1 | $15 |
| AstraZeneca | 1 | $14 |
| GRT US Holding, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Sunlenca$125
How this compares
$9,033 in reported general payments places this provider in the 95th percentile of 36 infectious disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 14 | $210,061 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 48 | $201,126 |
| RukobiaFostemsavir Tromethamine | 21 | $175,458 |
| JulucaDolutegravir/Rilpivirine | 40 | $152,608 |
| DovatoDolutegravir Sodium/Lamivudine | 38 | $134,526 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 21 | $77,862 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 18 | $76,669 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 14 | $50,725 |
| IsentressRaltegravir Potassium | 26 | $47,045 |
| PrezcobixDarunavir/Cobicistat | 13 | $29,488 |
| PrezistaDarunavir | 12 | $22,777 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 14 | $13,230 |
| Tigecycline | 12 | $4,649 |
| Doxycycline Hyclate | 24 | $3,214 |
| Daptomycin | 14 | $2,638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyRukobia, Juluca, Dovato | $1,655 | $462,59299 claims |
| GileadBiktarvy, Genvoya | $540 | $278,98869 claims |
| Insmed, Inc.Arikayce | $1,456 | $210,06114 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $445 | $76,66918 claims |
| MerckIsentress | $763 | $47,04526 claims |
| Johnson & JohnsonPrezcobix | $476 | $29,48813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 36 infectious disease providers in Mississippi.
Other infectious disease in Jackson
- Svenja AlbrechtJackson$5K
- Rathel NolanJackson$2K
- Richard FlowersJackson$1K
- Ujjwal DharJackson$1K
- Ayesha KhalidJackson$633
- Tulip JhaveriJackson$428
- Prakhar VijayvargiyaJackson$344
- Anne McPhersonJackson$294
- James BrockJackson$270
- Zerelda Esquer GarrigosJackson$214
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.